Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare RDS Tax May Prompt Employer Coverage Shifts, Focus On Rx Costs

Executive Summary

Prescription drug coverage for millions of retirees currently provided by for-profit employer plans may change in the coming years as a result of the new tax on the Medicare retiree drug subsidy, signed into law as part of health reform March 23

You may also be interested in...

Manufacturers’ Drug Discount Obligation Won’t Be Reduced In Part D Retiree Plans Under CMS Policy

A new Medicare Part D policy on calculating the 50% discount on branded drugs in the coverage gap will not allow for reduced manufacturer payments when beneficiaries are enrolled in employer group waiver plans, despite arguments from drug firms.

Impact Of Medicare RDS Tax Estimates Clarified; Employers Withhold Judgment On Reform Law

The upcoming tax on the Medicare retiree drug subsidy will be less harmful to large employers than recent accounting figures from a number of firms would suggest, House Energy and Commerce Committee staff report April 14.

Strategies To Ease Short-Term Earnings Pain From Health Reform Include Cost-Cutting, Diversification

With market-based fees and increased Medicaid rebates set to start several years before drug manufacturers will see any benefit of an expanded market from health care reform, consultants are suggesting several ways to counter the short-term negative effect on earnings, including continued cost-cutting and diversification

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts